Skip to main content

SYSTEMATIC REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1393404
This article is part of the Research Topic Community Series in Immunotherapy and Small Molecule Inhibitors as Combinational Cancer Therapeutics: Volume II View all 3 articles

Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis

Provisionally accepted
Changhui Zhou Changhui Zhou Weihua Wang Weihua Wang Ying Mu Ying Mu Min Meng Min Meng *
  • Liaocheng People's Hospital, Liaocheng, Shandong Province, China

The final, formatted version of the article will be published soon.

    Objective: To systematically evaluate the efficacy and safety of anlotinib targeted therapy for the treatment of patients with advanced digestive system neoplasms (DSNs).: Clinical trials were extracted from PubMed, the Cochrane Library, Web of Science, EmbaseEMBASE, China National Knowledge Infrastructure (CNKI)CNKI and the Wanfang database up to October 2023. Outcome measures, including therapeutic efficacy, quality of life (QOL) and adverse events, were extracted and evaluated. Results: Twenty trials, including 1,613 advanced DSNs patients, were included. The results indicated that, compared with conventional treatment alone, the combination of anlotinib targeted therapy with conventional treatment significantly improved the patients' 6-months overall survival (OS, OR=1.76, CI=1.53 to 2.02, P<0.00001), overall response (ORR, OR=1.76, CI=1.53 to 2.02, P<0.00001) and disease control rate (DCR, OR=1.51, 95% CI=1.25 to 1.84, P<0.0001). Moreover, the group that received the combined therapy had higher rates of hypertension (P<0.00001), proteinuria (P<0.00001), fatigue (P<0.00001), diarrhea (P<0.00001), hypertriglyceridemia (P=0.02), alanine aminotransfease (ALT)ALT increased (P=0.004), aspartate transaminase (AST) AST increased (P=0.006), anorexia (P<0.00001), weight loss (P=0.002), abdominal pain (P=0.0006), hypothyroidism (P=0.02), prolonged QT interval (P=0.04), ). whereas aAnalyses of other adverse events, such as gastrointestinal reaction, Leukopenialeukopenia, and 3 Neutropenianeutropenia, et al did not reveal significant differences (P>0.05).The combination of anlotinib targeted therapy and conventional treatment is more effective for DSNs treatment than conventional treatment alone.However, this combined treatment could lead to greater rates of hypertension, albuminuria and hand-foot syndrome. Therefore, the benefits and risks should be considered before treatment.

    Keywords: Anlotinib, target therapy, Conventional treatment, Digestive System Neoplasms, Meta-analysis

    Received: 29 Feb 2024; Accepted: 29 Jul 2024.

    Copyright: © 2024 Zhou, Wang, Mu and Meng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Min Meng, Liaocheng People's Hospital, Liaocheng, 252000, Shandong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.